ADC Linker & Conjugation Summit 2024

ADC Linker & Conjugation Summit, August 20-22, 2024, in Boston, MA

Join us at the Abzena booth to discuss the crucial role of linker payload architecture in the successful design of your drug candidate. Meet Rebecca Goydel, PhD, our Scientific Director of Business Development, and learn how our expertise in mAbs, linkers, and payloads can help you create a robust lead drug candidate. Discover how we can assist you in developing a safe and effective ADC drug by seamlessly integrating the desired linker, payload, and monoclonal antibody (mAb). Don’t miss this opportunity to leverage our extensive knowledge and enhance your drug development process.

Don’t miss our presentation on August 21st at 10:00 AM EST:  

Development of a site-specific and versatile conjugation approach based on bacterial transglutaminase and the Diels-Alder cycloaddition reaction for ADCs

This presentation will focus on the development of a novel two-step conjugation approach that combines the site specificity of the transglutaminase reaction with the reliability of the well-known Diels-Alder reaction to improve deliverability. 

  Attendees will gain insight into: 

•   The versatility of maleimides for the conjugation to antibodies – a different application that specifically conjugates via cycloaddition reaction vs conjugation to interchain disulfides or engineered cysteines. 
• Design and synthesis of the diene-containing linkers for site specific transglutaminase conjugation for two different payloads. 

• Evaluation of the in vitro and in vivo activity and stability of the ADCs generated via this transglutaminase – Diels-Alder approach.   

• The important role that Contract Research Organizations (CROs) can play in helping to discover and develop novel linker and conjugation technologies. 

Presenter: Francisco Velazquez, PhD, Sr. Director, Chemistry, Abzena

For more event information: Home – 2nd ADC Linker & Conjugation Summit (adc-linker-conjugation.com)

Schedule a meeting now: